EDG-5506: A Novel Small Molecule to Protect Dystrophic Muscle

Edgewise THERAPEUTICS

PPMD Connect Conference
June 23 – 26, 2021

Joanne M. Donovan, MD, PhD
Chief Medical Officer

Disclaimer

Disclaimer

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “estimate,” “intend,” “may,” “plan,” “potentially” “will” or the negative of these terms or other similar expressions.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: negative impacts of the COVID-19 pandemic on Edgewise’s operations, including clinical trials; risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; Edgewise’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in Edgewise’s plans to develop and commercialize EDG-5506 or any other product candidates; the potential for clinical trials of EDG-5506 or any other product candidates to differ from preclinical, preliminary or expected results; Edgewise’s ability to enroll patients in its ongoing and future clinical trials; operating results and business generally; Edgewise’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; Edgewise’s reliance on third parties, contract manufacturers and contract research organizations; Edgewise’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which Edgewise operates; Edgewise’s ability to develop a proprietary drug discovery platform to build a pipeline of product candidates; general economic and market conditions; and other risks. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation.

This presentation concerns drugs that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

EDG-5506 is an investigational drug and is not approved in any territory

In Dystrophic Muscle, Everyday Use Triggers Muscle Damage that Ultimately Leads to Loss of Function

When dystrophin is deficient or absent in Becker and Duchenne muscular dystrophy, the stress of everyday use of muscles triggers muscle damage that ultimately leads to loss of function.

The myofibrils that make up a muscle have important proteins called myosin. The interaction of myosin with other proteins causes muscle contraction, and delivers the power of muscles to conduct everyday activities.



Edgewise Approach: Protect Susceptible Muscle Fibers

In dystrophic muscle, certain muscle fibers, the fast muscle fibers, are more susceptible to damage due to the lack of dystrophin

We've designed an investigational therapy, **EDG-5506,** to protect fast muscle fibers from damage. Slow muscle fibers are not directly affected by **EDG-5506**



In animal models of muscular dystrophy, **EDG-5506** protected fast muscle fibers from injury, improved overall strength, and limited muscle wasting and the long-term development of fibrosis, including cardiomyopathy

We believe protecting fast fibers may prevent further muscle degeneration and slow disease progression; a Phase 1 clinical trial to test the effect of EDG-5506 on unaffected adults is ongoing

EDG-5506 Targets Myosin, the Key Protein to Drive Muscle Contraction, but only in Fast Muscle Fibers



- The key protein in muscle producing contraction is called *myosin*
- EDG-5506 *selectively inhibits* this protein *in fast fibers only*
- Our goal is to limit myosin to a level that *prevents breakdown but not healthy contraction*

- *In animal models of dystrophinopathy, EDG-5506 resulted in decreased CK and other biomarkers, as well as increased activity*

After Two Weeks of EDG-5506, CK, a Marker of Muscle Damage, Decreased, While Activity Increased in a Dog Model of DMD

Decreased injury biomarker (plasma CK)



Increased activity measured with an activity monitor



The Product Candidate: EDG-5506

- EDG-5506 is a small once daily tablet or liquid suspension
  - Potentially appropriate for any age and any mutation
- Phase 1 in unaffected adults is ongoing
- We are also enrolling adults with Becker for a short study to measure biomarkers and safety
- We are planning a Phase 2 study in adults and adolescents with Becker as well as an open label extension study to begin next year
- We are in the planning stages of a study in boys with Duchenne that we expect will start next year
- EDG-5506 potentially could be used in Duchenne, Becker, Limb-Girdle and other muscular dystrophies

Thank you!

For questions or comments please email us!

info@edgewisetx.com